Background: Minimal hepatic encephalopathy (HE) and HE grade 1 (HE1) according
| INTRODUCTION
Hepatic encephalopathy (HE) is a frequent and devastating complication of end-stage liver disease. It is defined as a reversible brain dysfunction which manifests with a wide spectrum of neuropsychiatric abnormalities caused by liver insufficiency and portosystemic shunting. 1, 2 Clinically, it includes neurological and psychiatric abnormalities ranging from subclinical alterations to coma. Depending on severity, HE is divided into two groups. Overt HE (OHE) presents episodically or continuously with obvious and clinically detectable symptoms. In contrast, covert HE (CHE) combines the two lowest grades of HEminimal HE (MHE) and HE grade 1 (HE1). 1 MHE alone affects up to 80% of cirrhotic patients in the course of their disease. [3] [4] [5] It is defined as evidence of neurocognitive impairment identified by neuropsychiatric tests in patients with no obvious clinical signs of HE, while HE1 is defined by the presence of mild clinical alterations like euphoria, anxiety or a shortened attention span. Although the consequences are serious, particularly CHE is often overlooked or even neglected in routine clinical practice due to only very mild symptoms (HE1) or not performed diagnostics (MHE). 6 Therefore, a distinction between OHE and CHE is relevant in clinical practice. Recent studies have demonstrated that CHE and especially MHE may lead to impairment of driving skills, increased rates of falls and most importantly poorer prognosis. [7] [8] [9] However, the impact of MHE on health-related quality of life (HRQoL) and sleep quality remains controversial. Particularly, in the past decade several studies have questioned a direct correlation. [10] [11] [12] [13] Although recommended in the current joint guideline of the European Association for the Study of the Liver (EASL) and the American Association for Study of Liver Diseases (AASLD), a recent study by Thomsen et al questioned whether HE1 and MHE should be grouped together under the term of CHE. Their study indicated that short time prognosis of patients with HE1 is less favourable compared to patients with MHE. 14 As a consequence, it has to be discussed whether HE1 and MHE should be grouped together, and, moreover, be treated in a similar way. More data on this controversial topic are therefore urgently needed.
From the patients 0 point of view, reduced quality of life and sleep disturbances may be important consequences of HE. In addition, a recent study demonstrated that particularly sleep disturbances are a major trigger of impaired HRQoL. 15 However, sound scientific data are lacking regarding the impact of CHE on these two relevant outcomes.
The aim of this study was first to determine whether CHE affects
HRQoL and sleep quality in a well-defined prospective cohort of cirrhotic patients and second, whether HE1 and MHE affect HRQoL and sleep-quality to a comparable extent supporting current classification. 16, 17 In total, 60 patients were excluded because they fulfilled one or more of the following exclusion criteria: previous episode of OHE during the last 6 weeks, chronic alcohol consumption during the last 3 months, any intake of psychotropic drugs or opioids, daltonism, the presence of pre-terminal comorbidities (heart disease NYHA III-IV, chronic obstructive pulmonary disease Gold C and D, renal failure with creatinine >1.5 mg/dL), the presence of hepatocellular carcinoma (HCC) or other active malignancies, a history of transjugular intrahepatic portosystemic shunt (TIPSS), active infection, neurological comorbidities (ie, dementia or history of stroke), or electrolyte disorders (serum potassium <3.5 mg/dL or >5 mg/dL, serum sodium <130 mg/dL or >150 mg/dL) ( Figure 1 ). Patients with a previous episode of OHE which took place longer than 6 weeks ago were allowed to participate if they were on consequent therapy with lactulose and/or rifaximin, if clinically indicated (n = 28). Reasons for hospitalisation were either to perform liver biopsy, ascites puncture, esophagogastroduodenoscopy with potential band ligation or evaluation for liver trans-
| PATIENTS AND METHODS

| Patients
plantation. Patients were never tested with PHES or CFF at the same day of any other intervention to rule out confounding factors.
| Diagnosis of HE
At first, every patient was examined by an experienced hepatologist to rule out OHE. The presence of HE1 has been assigned by the same hepatologist (CL) to every patient after detailed neurological examination according to the West Haven criteria. 1 The diagnosis was based on findings like euphoria, anxiety, lack of awareness, impaired performance of addition and/or shortened attention span as recommended in the current joint EASL/AASLD guideline. patients. Interpretation of PHES was done as previously described with German norms. 18 All tests were conducted by trained medical staff and performed in a quiet, lighted room between 09:00 AM and 04:00 PM. A score <-4 was considered as pathological. 18 After testing with PHES, CFF was measured using the validated HEPAtonorm-Analyzer© 2.0 (nevoLAB GmbH, Maierhoefen, Germany). CFF was conducted by trained medical staff in a quiet, semi darkened room between 09:00 AM and 04:00 PM. Results <39 Hz were considered as pathological. 19 After instruction, the patient had a training phase with at least 4 measurements to adapt to the procedure. Finally, eight measurements were conducted and a mean was calculated.
Both tests were carried out on the same day with the respective patient. 
| Assessment of HRQoL
| Assessment of sleep quality
The 
| Ethics
The study was conducted according to the ethical guidelines of the 
| Statistical analysis
| RESULTS
A total of 145 cirrhotic in-and out-patients fulfilling the inclusion and exclusion criteria were prospectively studied between March 2017 and January 2018. Almost 60% of patients were male with a median age of 60 years (range 
| Predictors of poor HRQoL in cirrhotic patients
In the total cohort, CHE (standardised b coefficient = 0.308, R 2 = .135, P < 0.001) and female gender (standardised b coefficient = À0.234, R 2 = .135, P = 0.006) were the only independent factors associated with poor HRQoL (CLDQ total score) by multivariate linear regression analysis (Table 2) we repeated the analysis, now excluding patients with MHE. In this specific sub-analysis, HE1 did not turn out as an independent factor for poor HRQoL (data not shown).
| Predictors of poor sleep quality in cirrhotic patients
In the total cohort, CHE (standardised b coefficient = À0.207, (Table 4 ).
| Comparison of patients with HE1 and MHE
In total, 59 patients were diagnosed with CHE (Table 5 ). Of these, 19 had HE1 and 40 MHE. Age, gender, school education, proportion of out-patients and aetiology of cirrhosis did not differ between both groups. MELD and CP scores were higher in patients with HE1.
The proportion of patients with a history of OHE was higher in the HE1 group, whereas the proportions of ascites at study entry or a history of ascites were comparable between both groups. In addition, patients with HE1 exhibited higher serum levels of bilirubin and IL-6 and lower levels of albumin. Comparable results in CLDQ and PSQI total scores were noted for both groups (Figure 3) . Furthermore, there was no difference in the frequency of poor sleepers (Table 5 ). contrast, our study compromises a much larger population of cirrhotic patients with and without CHE.
| DISCUSSION
The pathogenesis of poor sleep quality in patients with liver cirrhosis is multifactorial and poorly understood. Our study identified 69% of cirrhotic patients as poor sleepers. These numbers are in accordance with recent findings from other Western countries (60%-81%). 13, 15 In addition, we could demonstrate that CHE and also MHE alone are independent risk factors for poor sleep quality in cirrhotic patients. These results are in contrast with findings of recently published studies conducted in Asian and Italian populations. 12, 13 Again, the heterogeneity of different diagnostic procedures to establish the diagnosis of MHE may be a possible explanation. Furthermore, Tsai et al excluded all patients with alcoholic liver cirrhosis. In our study, alcohol was the leading aetiology of underlying liver disease affecting 34.4% of patients. It is well known that chronic alcohol consumption may lead to an impairment of cognitive functions 28 and to the dysregulation of sleep and insomnia in phases of heavy alcohol drinking as well as in phases of abstinence.
29,30
However, we excluded patients with a history of alcohol intake during the last 3 months. Furthermore, alcohol intake did not turn out as an independent predictor for poor sleep quality in our cohort. Therefore, a potential bias seems unlikely.
The cohort characteristics in the study by Montagnese et al are better comparable to ours. 13 Hence, some differences in results may be explained by the different study sizes. The Italian cohort consisted of 29 patients with HE, only. Of these, 12 were classified as It has to be mentioned that HE1 had only a significant correlation with HRQoL and sleep quality in the univariate analysis. This may be most likely attributed to a type II error, especially when taken into consideration that CHE was an independent risk factor for both HRQoL and sleep quality.
In addition to CHE and MHE, female gender was associated with reduced HRQoL and poor sleep quality. Regarding HRQoL, this finding is in line with other studies investigating the quality of life in patients with chronic liver diseases. 32, 33 One explanation may be a different self-perception of health between women and men. A main reason for this difference could be the stigmatisation and the negative perception of the diagnosis-liver cirrhosis-in western countries which seems to affect women to a larger extent than men.
However, our data contrast with other studies in this field, which have been mentioned before. 10, 11 Again, this may be most likely attributed to a type II error of the other studies, since most of these only included a small number of females. Furthermore, we identified an association between lower haemoglobin levels and poor sleep quality. This may be not surprising, because low haemoglobin levels are a well-established risk factor for sleep disturbances, for example, in end-stage kidney disease. 34, 35 There are several limitations of our study. First of all, patients included were enrolled at a single large German transplant centre.
Consequently, there could be a referral bias. For this reason, our findings may not be generalisable to all cirrhotic patients. In addition, the study lacks a control group with healthy individuals. However, because we compared patients with and without CHE, this should not impact on the main conclusions of our study. Furthermore, it has to be mentioned that our patients were not screened for undiagnosed OSAS or other known causes for impaired sleep quality. Our observation that a known risk factor for this condition like male gender did not turn out as a significant predictor of reduced quality of life and sleep disturbances argue against a relevant effect of other factors that might have a significant impact on sleep. However, the STOP-Bang questionnaire may be used in future clinical investigations in this field. In addition, HRQoL and sleep quality were only assessed on one defined day. Therefore, fluctuations cannot be easily judged on the ground of the presented data. Studies with repeated assessments are required to investigate the course of
HRQoL and sleep quality in cirrhotic patients. Last, it has to be mentioned that some of the correlations are relatively weak and therefore interpretation should be done cautiously.
In conclusion, we could demonstrate for the first time in a large prospective cohort that CHE is an independent risk factor for impaired HRQoL and sleep quality in cirrhotic patients. In addition, our data revealed for the first time that HE1 and MHE affect these important patient-related outcomes to a comparable extent. As a consequence, and most importantly, our data support the use of CHE as a useful and valid term for cirrhotic patients with both entities of HE in clinical practice. 
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